Hundreds of CRISPR patents have been granted around the world, and the number of applications continues to grow at a rapid pace.

The US patent office declares an interference between the intellectual property held by the Broad Institute and several patent applications filed by the University of California—opposite its previous ruling.

The higher court’s decision to uphold the ruling of the Patent Trial and Appeal Board essentially ends the intellectual property battle in the US.

In an ongoing legal battle, the University of California, Berkeley has challenged the Broad Institute’s patent claims on the gene editing technology.

Gender discrimination, Brexit, and climate change are among the issues that have received considerable attention from the scientific community this year.

The battle for the control of the intellectual property surrounding CRISPR-Cas9 is as storied and nuanced as the technology itself.

The University of California files a brief in its appeal challenging the ruling that the Broad Institute’s group would retain its CRISPR genome-editing patent.

This week’s CRISPR patent hearing took a deep dive into the science of moving the gene-editing technology from prokaryotes to eukaryotic systems.

Meet some of the people featured in the October 2016 issue of The Scientist